Karyopharm Therapeutics reported $79.31M in Operating Expenses for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
AstraZeneca AZN:LN 12.3B 763M
Avrobio Inc AVRO:US 29.42M 1.46M
Enanta Pharmaceuticals ENTA:US $ 52.56M 5.49M
Mirati Therapeutics MRTX:US $ 184.93M 12.45M
Nektar Therapeutics NKTR:US $ 137.92M 598K
Novartis NOVN:VX 10.96B 826M
Sangamo Biosciences SGMO:US $ 73.49M 5.61M
Tg Therapeutics TGTX:US $ 95.27M 8.11M
Xencor XNCR:US $ 59.03M 3.33M